Cite
HARVARD Citation
Miller, K. et al. (n.d.). 824PRadium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of oncology. p. . [Online].